Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Senti Biosciences Holdings Inc (SNTI)

Senti Biosciences Holdings Inc (SNTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 GlobeNewswire - Mon Apr 13, 8:00AM CDT

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies GlobeNewswire - Wed Apr 1, 7:45AM CDT

SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update GlobeNewswire - Fri Mar 27, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference GlobeNewswire - Mon Mar 23, 8:00AM CDT

SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference GlobeNewswire - Tue Mar 3, 8:05AM CST

SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference GlobeNewswire - Tue Feb 24, 8:15AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development GlobeNewswire - Fri Feb 20, 7:50AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) GlobeNewswire - Wed Feb 11, 7:35AM CST

Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202...

SNTI : 0.9834 (-0.17%)
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 GlobeNewswire - Tue Feb 3, 8:00AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 0.9834 (-0.17%)
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation GlobeNewswire - Wed Jan 14, 8:15AM CST

Access the segment  here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing...

SNTI : 0.9834 (-0.17%)

Barchart Exclusives

As CPUs Steal the Show, AMD Stock Just Got a New Street-High Price Target Barchart - 7 minutes ago
Agentic AI is creating a fresh opportunity for AMD, with its booming server CPU business fueling strong growth, fresh optimism, and a new Street-high price target. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.